Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05575076 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension for Phase 3 Clinical Trials of Simufilam
A Phase 3 study, sponsored by Cassava Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,081
- Enrollment target
NCT05575076: Clinical Trial Phase 3 study, sponsored by Cassava Sciences.
NCT05575076 is a Phase 3 study that was terminated before completion, run by Cassava Sciences. The registered enrollment target is 1,081 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05575076, a Phase 3 study, was terminated before completion, sponsored by Cassava Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,081 participants
- Enrollment target
Study Summary
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
Primary Outcome
To evaluate the long-term safety and tolerability of simufilam 100 mg tablets in subjects who have completed one of the two double-blind simufilam phase 3 studies.
Interventions
- DRUG Simufilam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,081 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 3 |
Why NCT05575076 stopped before completion
NCT05575076 is an interventional study that assigns participants to a tested intervention. Its 1,081 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 1 intervention - of which Simufilam is the first listed.
NCT05575076 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05575076 about?
NCT05575076 is a clinical study titled "Open-label Extension for Phase 3 Clinical Trials of Simufilam". The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
What is the current status of trial NCT05575076?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,081 participants. The study started on 2022-11-07. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05575076?
The interventions under investigation include: Simufilam (DRUG).
Who is sponsoring clinical trial NCT05575076?
This trial is sponsored by Cassava Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05575076's enrollment target sits among peer trials
1,081 269th of 2000 higher than 1,732 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI